{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:53Z","timestamp":1792788113157,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation","award":["774\/19"],"award-info":[{"award-number":["774\/19"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Federico Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/022jgqd87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Federico Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/022jgqd87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Israel Science Foundation, Federico Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/04sazxf24","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04388-y","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:25:42Z","timestamp":1783409142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["M196R-TNFR2 and membrane TNF\u03b1 down-regulate soluble TNF\u03b1-induced pro-metastatic functions in triple-negative breast cancer cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Shelly","family":"Adam-Shlanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Porat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Baram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsipi","family":"Meshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Dadiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nofar","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abu Raiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Horvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Liubomirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Kizelsztein Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Meshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Korner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Balint-Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Pavlovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Morzaev-Sulzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav Nili","family":"Gal-Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Barschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Ben-Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"4388_CR1","doi-asserted-by":"publisher","first-page":"903679","DOI":"10.3389\/fimmu.2022.903679","volume":"13","author":"A Ben-Baruch","year":"2022","unstructured":"Ben-Baruch A. Tumor Necrosis Factor alpha: Taking a personalized road in cancer therapy. Front Immunol. 2022;13:903679.","journal-title":"Front Immunol"},{"key":"4388_CR2","doi-asserted-by":"publisher","first-page":"102409","DOI":"10.1016\/j.coi.2023.102409","volume":"86","author":"LF Alim","year":"2024","unstructured":"Alim LF, Keane C, Souza-Fonseca-Guimaraes F. Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Curr Opin Immunol. 2024;86:102409.","journal-title":"Curr Opin Immunol"},{"key":"4388_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"4388_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12929-017-0398-9","volume":"24","author":"I Martinez-Reza","year":"2017","unstructured":"Martinez-Reza I, Diaz L, Garcia-Becerra R. Preclinical and clinical aspects of TNF-alpha and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci. 2017;24:90.","journal-title":"J Biomed Sci"},{"key":"4388_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14740\/wjon2532","volume":"16","author":"N Qodir","year":"2025","unstructured":"Qodir N, Pramudhito D, Legiran, Hafy Z, Iman MB, Syafira F, Afladhanti PM, Daenasa RS, Indra B. Tumor Necrosis Factor-Alpha and its association with breast cancer: A systematic review. World J Oncol. 2025;16:143\u201351.","journal-title":"World J Oncol"},{"key":"4388_CR6","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/cancers14174280","volume":"14","author":"R Mahmoud","year":"2022","unstructured":"Mahmoud R, Ordonez-Moran P, Allegrucci C. Challenges for triple negative breast cancer treatment: Defeating heterogeneity and cancer stemness. Cancers (Basel). 2022;14:4280\u201394.","journal-title":"Cancers (Basel)"},{"key":"4388_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluwe A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9:7.","journal-title":"NPJ Breast Cancer"},{"key":"4388_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12967-025-06122-0","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Ye R, Dai H, Lin J, Cheng Y, Zhou Y, Lu Y. Exploring TNFR1: from discovery to targeted therapy development. J Transl Med. 2025;23:71.","journal-title":"J Transl Med"},{"key":"4388_CR9","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/cells11121952","volume":"11","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Yoshimatsu G, Faustman DL. The Roles of TNFR2 signaling in cancer cells and the tumor microenvironment and the potency of TNFR2 targeted therapy. Cells. 2022;11:1952.","journal-title":"Cells"},{"key":"4388_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/physrev.00045.2017","volume":"99","author":"C Dostert","year":"2019","unstructured":"Dostert C, Grusdat M, Letellier E, Brenner D. The TNF Family of ligands and receptors: Communication modules in the immune system and beyond. Physiol Rev. 2019;99:115\u201360.","journal-title":"Physiol Rev"},{"key":"4388_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","volume":"83","author":"M Grell","year":"1995","unstructured":"Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80\u00a0kDa tumor necrosis factor receptor. Cell. 1995;83:793\u2013802.","journal-title":"Cell"},{"key":"4388_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1349-7006.2006.00277.x","volume":"97","author":"I Garcia-Tunon","year":"2006","unstructured":"Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 2006;97:1044\u20139.","journal-title":"Cancer Sci"},{"key":"4388_CR13","doi-asserted-by":"publisher","first-page":"205873841878799","DOI":"10.1177\/2058738418787990","volume":"32","author":"A Autenshlyus","year":"2018","unstructured":"Autenshlyus A, Arkhipov S, Mikhailova E, Arkhipova V, Varaksin N. VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these malignant tumors. Int J Immunopathol Pharmacol. 2018;32:2058738418787990.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4388_CR14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3892\/ol.2017.6410","volume":"14","author":"F Yang","year":"2017","unstructured":"Yang F, Zhao Z, Zhao N. Clinical implications of tumor necrosis factor receptor 2 in breast cancer. Oncol Lett. 2017;14:2393\u20138.","journal-title":"Oncol Lett"},{"key":"4388_CR15","doi-asserted-by":"publisher","first-page":"720472","DOI":"10.3389\/fcell.2021.720472","volume":"9","author":"Q Fu","year":"2021","unstructured":"Fu Q, Shen Q, Tong J, Huang L, Cheng Y, Zhong W. Anti-tumor necrosis factor receptor 2 antibody combined with anti-PD-L1 therapy exerts robust antitumor effects in breast cancer. Front Cell Dev Biol. 2021;9:720472.","journal-title":"Front Cell Dev Biol"},{"key":"4388_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2407-11-130","volume":"11","author":"G Soria","year":"2011","unstructured":"Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011;11:130.","journal-title":"BMC Cancer"},{"key":"4388_CR17","doi-asserted-by":"publisher","first-page":"494581","DOI":"10.1155\/2014\/494581","volume":"2014","author":"XL Zhou","year":"2014","unstructured":"Zhou XL, Fan W, Yang G, Yu MX. The clinical significance of PR, ER, NF- kappa B, and TNF- alpha in breast cancer. Dis Markers. 2014;2014:494581.","journal-title":"Dis Markers"},{"key":"4388_CR18","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1158\/0008-5472.CAN-12-3946","volume":"73","author":"M Yu","year":"2013","unstructured":"Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, Gan H, Wang J, Jiang X, Yin B, Li Z. Targeting transmembrane TNF-alpha suppresses breast cancer growth. Cancer Res. 2013;73:4061\u201374.","journal-title":"Cancer Res"},{"key":"4388_CR19","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1038\/s41388-018-0221-4","volume":"37","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Lin G, Yan Y, Li X, Hu Y, Wang J, Yin B, Wu Y, Li Z, Yang XP. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. Oncogene. 2018;37:3456\u201370.","journal-title":"Oncogene"},{"key":"4388_CR20","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/bcr1648","volume":"9","author":"C Chavey","year":"2007","unstructured":"Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9:R15.","journal-title":"Breast Cancer Res"},{"key":"4388_CR21","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1073\/pnas.1518808112","volume":"112","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015;112:14325\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4388_CR22","doi-asserted-by":"publisher","first-page":"122982","DOI":"10.1016\/j.lfs.2024.122982","volume":"354","author":"D Cruceriu","year":"2024","unstructured":"Cruceriu D, Balacescu L, Baldasici O, Gaal OI, Balacescu O, Russom A, Irimia D, Tudoran O. Gene expression-phenotype association study reveals the dual role of TNF-alpha\/TNFR1 signaling axis in confined breast cancer cell migration. Life Sci. 2024;354:122982.","journal-title":"Life Sci"},{"key":"4388_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12929-023-00986-4","volume":"30","author":"SH Chan","year":"2023","unstructured":"Chan SH, Kuo WH, Wang LH. SCEL regulates switches between pro-survival and apoptosis of the TNF-alpha\/TNFR1\/NF-kappaB\/c-FLIP axis to control lung colonization of triple negative breast cancer. J Biomed Sci. 2023;30:93.","journal-title":"J Biomed Sci"},{"key":"4388_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.neo.2018.03.004","volume":"20","author":"SP Egusquiaguirre","year":"2018","unstructured":"Egusquiaguirre SP, Yeh JE, Walker SR, Liu S, Frank DA. The STAT3 Target Gene TNFRSF1A Modulates the NF-kappaB Pathway in Breast Cancer Cells. Neoplasia. 2018;20:489\u201398.","journal-title":"Neoplasia"},{"key":"4388_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41419-023-05718-y","volume":"14","author":"EM Meskyte","year":"2023","unstructured":"Meskyte EM, Pezze L, Bartolomei L, Forcato M, Bocci IA, Bertalot G, Barbareschi M, Oliveira-Ferrer L, Bisio A, Bicciato S, et al. ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1\/NF-kappaB axis. Cell Death Dis. 2023;14:263.","journal-title":"Cell Death Dis"},{"key":"4388_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.yexcr.2007.10.005","volume":"314","author":"MA Rivas","year":"2008","unstructured":"Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42\/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res. 2008;314:509\u201329.","journal-title":"Exp Cell Res"},{"key":"4388_CR27","doi-asserted-by":"publisher","first-page":"101042831769226","DOI":"10.1177\/1010428317692264","volume":"39","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Yang F, Li W, Xu C, Li L, Chen L, Liu Y, Sun P. miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. Tumour Biol. 2017;39:1010428317692264.","journal-title":"Tumour Biol"},{"key":"4388_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neo.2020.12.007","volume":"23","author":"L He","year":"2021","unstructured":"He L, Bhat K, Duhacheck-Muggy S, Ioannidis A, Zhang L, Nguyen NT, Moatamed NA, Pajonk F. Tumor necrosis factor receptor signaling modulates carcinogenesis in a mouse model of breast cancer. Neoplasia. 2021;23:197\u2013209.","journal-title":"Neoplasia"},{"key":"4388_CR29","doi-asserted-by":"publisher","first-page":"1227003","DOI":"10.3389\/fimmu.2023.1227003","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, Plebanski M. Editorial: The role of TNF-TNFR2 signal in immunosuppressive cells and its therapeutic implications, II. Front Immunol. 2023;14:1227003.","journal-title":"Front Immunol"},{"key":"4388_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00262-020-02549-0","volume":"69","author":"M Dadiani","year":"2020","unstructured":"Dadiani M, Necula D, Kahana-Edwin S, Oren N, Baram T, Marin I, Morzaev-Sulzbach D, Pavlovski A, Balint-Lahat N, Anafi L, et al. TNFR2\u2009+\u2009TILs are significantly associated with improved survival in triple-negative breast cancer patients. Cancer Immunol Immunother. 2020;69:1315\u201326.","journal-title":"Cancer Immunol Immunother"},{"key":"4388_CR31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/cells10061429","volume":"10","author":"T Baram","year":"2021","unstructured":"Baram T, Erlichman N, Dadiani M, Balint-Lahat N, Pavlovski A, Meshel T, Morzaev-Sulzbach D, Gal-Yam EN, Barshack I, Ben-Baruch A. Chemotherapy Shifts the Balance in Favor of CD8\u2009+\u2009TNFR2+ TILs in Triple-Negative Breast Tumors. Cells. 2021;10:1429.","journal-title":"Cells"},{"key":"4388_CR32","doi-asserted-by":"publisher","first-page":"e101138","DOI":"10.1371\/journal.pone.0101138","volume":"9","author":"F Xu","year":"2014","unstructured":"Xu F, Zhou G, Han S, Yuan W, Chen S, Fu Z, Li D, Zhang H, Li D, Pang D. Association of TNF-alpha, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women. PLoS ONE. 2014;9:e101138.","journal-title":"PLoS ONE"},{"key":"4388_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2005.01.007","volume":"30","author":"S Mestiri","year":"2005","unstructured":"Mestiri S, Bouaouina N, Ben Ahmed S, Chouchane L. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine. 2005;30:182\u20137.","journal-title":"Cytokine"},{"key":"4388_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/1471-2407-11-447","volume":"11","author":"X Guan","year":"2011","unstructured":"Guan X, Liao Z, Ma H, Qian J, Liu Z, Yuan X, Gomez D, Komaki R, Wang LE, Wei Q. TNFRSF1B\u2009+\u2009676 T\u2009>\u2009G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2011;11:447.","journal-title":"BMC Cancer"},{"key":"4388_CR35","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1074\/jbc.M411541200","volume":"280","author":"A Till","year":"2005","unstructured":"Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJ, Schafer H, Scheurich P, Seegert D, Schreiber S. The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem. 2005;280:5994\u20136004.","journal-title":"J Biol Chem"},{"key":"4388_CR36","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/cancers14143513","volume":"14","author":"T Baram","year":"2022","unstructured":"Baram T, Oren N, Erlichman N, Meshel T, Ben-Baruch A. Inflammation-driven regulation of PD-L1 and PD-L2, and their cross-interactions with protective soluble TNFalpha receptors in human triple-negative breast cancer. Cancers (Basel). 2022;14:3513\u201340.","journal-title":"Cancers (Basel)"},{"key":"4388_CR37","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1007\/s11033-021-06648-8","volume":"48","author":"A Mishra","year":"2021","unstructured":"Mishra A, Suman KH, Nair N, Majeed J, Tripathi V. An updated review on the role of the CXCL8-CXCR1\/2 axis in the progression and metastasis of breast cancer. Mol Biol Rep. 2021;48:6551\u201361.","journal-title":"Mol Biol Rep"},{"key":"4388_CR38","doi-asserted-by":"publisher","first-page":"14710","DOI":"10.1073\/pnas.1408556111","volume":"111","author":"P Guo","year":"2014","unstructured":"Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. 2014;111:14710\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4388_CR39","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cancers15102734","volume":"15","author":"D Li","year":"2023","unstructured":"Li D, Hemati H, Park Y, Taftaf R, Zhang Y, Liu J, Cristofanilli M, Liu X. ICAM-1-suPAR-CD11b axis is a novel therapeutic target for metastatic triple-negative breast cancer. Cancers (Basel). 2023;15:2734.","journal-title":"Cancers (Basel)"},{"key":"4388_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41419-025-07609-w","volume":"16","author":"A Albini","year":"2025","unstructured":"Albini A, Di Paola L, Mei G, Baci D, Fusco N, Corso G, Noonan D. Inflammation and cancer cell survival: TRAF2 as a key player. Cell Death Dis. 2025;16:292.","journal-title":"Cell Death Dis"},{"key":"4388_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/apt.12010","volume":"36","author":"C Steenholdt","year":"2012","unstructured":"Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and\/or acute severe infusion reactions to infliximab in Crohn\u2019s disease. Aliment Pharmacol Ther. 2012;36:650\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"4388_CR42","doi-asserted-by":"publisher","first-page":"e003837","DOI":"10.1136\/jitc-2021-003837","volume":"11","author":"H Ba","year":"2023","unstructured":"Ba H, Dai Z, Zhang Z, Zhang P, Yin B, Wang J, Li Z, Zhou X. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. J Immunother Cancer. 2023;11:e003837.","journal-title":"J Immunother Cancer"},{"key":"4388_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-008-0111-5","volume":"116","author":"D Yan","year":"2009","unstructured":"Yan D, Qin N, Zhang H, Liu T, Yu M, Jiang X, Feng W, Wang J, Yin B, Zhang T, et al. Expression of TNF-alpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-alpha. Breast Cancer Res Treat. 2009;116:91\u2013102.","journal-title":"Breast Cancer Res Treat"},{"key":"4388_CR44","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41418-019-0441-3","volume":"27","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang Y, Zhou S, He X, Cao X, Wu C, Hu H, Qin J, Wei G, Wang H, et al. Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling. Cell Death Differ. 2020;27:1569\u201387.","journal-title":"Cell Death Differ"},{"key":"4388_CR45","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/0008-5472.CAN-13-0002","volume":"73","author":"S Ardestani","year":"2013","unstructured":"Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-alpha exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res. 2013;73:3938\u201350.","journal-title":"Cancer Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04388-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:50:59Z","timestamp":1789527059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04388-y","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"312"}}